IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Nature
Sevin TurcanTimothy A Chan

Abstract

Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural ...Continue Reading

Associated Clinical Trials

References

May 16, 1998·Genome Research·D GordonP Green
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·M ToyotaJ P Issa
Nov 29, 2002·Frontiers in Bioscience : a Journal and Virtual Library·Russell O Pieper
Sep 4, 2003·Genome Research·Paul D ThomasApurva Narechania
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Apr 19, 2006·Genes & Development·Adrian P BrackenKristian Helin
Apr 28, 2006·Nature Genetics·Michael ReichJill P Mesirov
Sep 9, 2006·Science·Tobias SjöblomVictor E Velculescu
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
May 31, 2007·Neoplasia : an International Journal for Oncology Research·Daniel R RhodesArul M Chinnaiyan
Jun 30, 2007·Bioinformatics·John E Major
Nov 3, 2007·Genes & Development·Frank B FurnariWebster K Cavenee
Apr 3, 2008·Cancer Research·David A SolomonTodd Waldman
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu-Wei ChengFrancis Barany
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
May 22, 2009·The New England Journal of Medicine·Emilie De CarliStéphanie Puget
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Apr 20, 2010·Cancer Cell·Houtan NoushmehrUNKNOWN Cancer Genome Atlas Research Network
Dec 16, 2010·BMC Genomics·Amandine EtcheverryJean Mosser
Mar 25, 2011·Science Translational Medicine·Fang FangTimothy A Chan
May 20, 2011·Epigenetics : Official Journal of the DNA Methylation Society·Juan SandovalManel Esteller
Aug 16, 2011·Genomics·Marina BibikovaRichard Shen

❮ Previous
Next ❯

Citations

Jun 19, 2013·Der Nervenarzt·M PlattenW Wick
Mar 21, 2013·Acta Neuropathologica·Craig Horbinski
Jan 9, 2013·Pflügers Archiv : European journal of physiology·Daniel Medina-Cleghorn, Daniel K Nomura
Mar 9, 2012·Brain Tumor Pathology·Koichi Ichimura
Sep 8, 2012·Current Treatment Options in Oncology·Adriana Olar, Kenneth D Aldape
Mar 28, 2013·Current Neurology and Neuroscience Reports·Adam L CohenHoward Colman
Nov 6, 2012·Current Oncology Reports·Derek R Johnson, Evanthia Galanis
Jul 17, 2012·Current Treatment Options in Neurology·Shaheryar Hafeez, Robert Cavaliere
Oct 23, 2013·Trends in Molecular Medicine·Irfan A Qureshi, Mark F Mehler
Mar 29, 2012·Cell Research·Dan YeKun-Liang Guan
Apr 25, 2013·European Journal of Human Genetics : EJHG·Juliette Aury-LandasJean-Michel Flaman
May 31, 2013·Journal of Human Genetics·Shinjiro HinoMitsuyoshi Nakao
Jun 7, 2013·Journal of Human Genetics·Kiyoshi AsadaToshikazu Ushijima
Jan 12, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Shuji OginoEdward Giovannucci
Oct 25, 2013·Nature·Philipp Gut, Eric Verdin
Jul 19, 2013·Nature Communications·Paul GuilhamonStephan Beck
Sep 11, 2013·Nature Communications·Myriam M ChaumeilSabrina M Ronen
Jul 31, 2013·Nature Genetics·Sevin Turcan, Timothy A Chan
Jul 10, 2012·Nature Medicine·Regina M Young, M Celeste Simon
Sep 3, 2013·Nature Neuroscience·William A FlavahanAnita B Hjelmeland
Sep 25, 2012·Nature Reviews. Cancer·Douglas C Wallace
Oct 12, 2013·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Sep 5, 2012·Nature Reviews. Genetics·Holger Heyn, Manel Esteller
Oct 10, 2013·Nature Reviews. Genetics·Christoph PlassPeter Lichter
Jan 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Siming ZhaoAlessandro D Santin
Dec 18, 2013·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Satoshi OgasawaraYukinari Kato
Apr 19, 2013·Neuro-oncology·Benedikt WiestlerUNKNOWN Neuro-oncology Working Group (NOA) of the German Cancer Society
Oct 1, 2013·Current Opinion in Oncology·Laure ThomasFrançois Ducray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.